2024-02-23 06:03:58 ET
Summary
- Rhythm Pharmaceuticals focuses on treating obesity caused by genetic mutations, but the market size for these mutations is too small to justify the company's valuation.
- Novo Nordisk's Ozempic also targets the same patient groups, making Rhythm's product less appealing.
- IMCIVREE, Rhythm's main product, shows good results in clinical trials, but again the action is too specific. Outstanding dilution from options too down the line.
- Not for us.
...
Read the full article on Seeking Alpha
For further details see:
Rhythm Pharmaceuticals: Action Too Specific